What Happened?
A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy costs.
For healthcare providers and medical device manufacturers, lower oil prices directly reduce the cost of operating large hospital facilities and shipping sensitive medical equipment. This margin relief is vital for a sector that has been squeezed by high transportation overhead, allowing for a more favorable outlook on quarterly earnings. The "risk-on" sentiment sparked by the ceasefire is also driving capital back into high-growth biotech and pharmaceutical names.
As broader market volatility recedes, investors are more willing to fund long-term R&D and clinical trials that were previously shadowed by macroeconomic uncertainty. The stabilization of the global economy ensures that both elective procedures and pharmaceutical demand remain on a steady upward trajectory for the remainder of 2026.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Research Tools & Consumables company Bruker (NASDAQ: BRKR) jumped 3.7%. Is now the time to buy Bruker? Access our full analysis report here, it’s free.
- Generic Pharmaceuticals company Amneal (NASDAQ: AMRX) jumped 5.2%. Is now the time to buy Amneal? Access our full analysis report here, it’s free.
- Generic Pharmaceuticals company Amphastar Pharmaceuticals (NASDAQ: AMPH) jumped 4.4%. Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here, it’s free.
- Dental Equipment & Technology company Dentsply Sirona (NASDAQ: XRAY) jumped 4%. Is now the time to buy Dentsply Sirona? Access our full analysis report here, it’s free.
- Genomics & Sequencing company PacBio (NASDAQ: PACB) jumped 3.7%. Is now the time to buy PacBio? Access our full analysis report here, it’s free.
Zooming In On Amneal (AMRX)
Amneal’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock gained 8.9% on the news that the company reported strong third-quarter financial results that surpassed expectations and raised its full-year forecast.
The pharmaceutical company posted adjusted earnings of $0.17 per share for the quarter, beating analyst estimates. Revenue also topped forecasts, reaching $785 million, which represented a 12% increase compared to the same period in the prior year. Bolstered by these results, Amneal provided an improved outlook for the full year. The company revised its projections for net revenue to a range between $3.0 billion and $3.1 billion and lifted its forecast for adjusted earnings per share to between $0.75 and $0.80.
Amneal is up 9.6% since the beginning of the year, and at $13.87 per share, it is trading close to its 52-week high of $15.19 from February 2026. Investors who bought $1,000 worth of Amneal’s shares 5 years ago would now be looking at an investment worth $2,442.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
